Company: STAA
Filing Date: 2025-08-29
Form Type: PREM14A
Source: 0001193125-25-192889
Chunk: 55

Company: STAAR SURGICAL CO
Filing Date: 2025-08-29
Form: PREM14A
Chunk 55
---
, among other things, (i) the continuation of, and potential improvements to, STAAR’s standalone business plan; (ii) capital
allocation initiatives; (iii) potential expansion opportunities through acquisitions, partnerships or other commercial relationships; and (iv) business combinations and other financial and strategic alternatives, including the sale of some
or all of STAAR. The Board and members of STAAR’s management also have regularly engaged with STAAR’s stockholders to discuss their perspectives on STAAR’s strategic and financial direction.

As active participants in the eye care industry, STAAR and Alcon are well known to each other. From time to time, members of STAAR’s
management have met with members of Alcon’s management to discuss the industry and their respective businesses. At various points in the past, STAAR and Alcon discussed consolidation in their industry and the potential for a business
combination transaction between STAAR and Alcon.

On April 9, 2024, Thomas Frinzi, who was then serving as Chair of the Board,
President and Chief Executive Officer of STAAR, and David Endicott, the Chief Executive Officer of Alcon, engaged in discussions regarding industry dynamics and the strategic opportunities and challenges that both STAAR and Alcon face. During these
discussions, Mr. Endicott expressed his interest in discussing a potential business combination

-35-

between the two companies. Mr. Frinzi indicated to Mr. Endicott that STAAR was focused on the execution of its standalone business plan, but that he would bring any proposal that Alcon
made to the Board for consideration. Thereafter, Mr. Frinzi reported his conversation with Mr. Endicott to members of the Board.

On April 19, 2024, Mr. Endicott sent Mr. Frinzi a non-binding offer letter (the
“April Offer”) proposing that Alcon would acquire 100% of STAAR common stock for $58.00 per share in cash. On April 19, 2024, the trading price of STAAR common stock closed at $46.39 per share. Mr. Frinzi discussed the terms of
the April Offer with members of the Board.

Also on April 19, 2024, Mr. Frinzi and Mr. Endicott met in person, and
Mr. Frinzi conveyed that, based on his discussions with the members of the Board, STAAR would continue working to execute its standalone business plan.

On